In a significant move within the pharmaceutical sector, Torrent Pharmaceuticals, an Indian company, is set to acquire a controlling stake of 46.39% in JB Chemicals and Pharmaceuticals from global investment firm KKR. This transaction, valued at ₹119 billion (approximately .4 billion), positions JB Pharma’s market capitalization at ₹256.89 billion (.01 billion). The acquisition aligns with Torrent’s strategy to develop a “diversified pharmaceutical platform for the future.”
Strategic Expansion and Future Prospects
Following the acquisition of KKR’s stake, Torrent Pharmaceuticals may also purchase an additional 26% of shares from minority shareholders and up to 2.8% from JB Pharma employees. This strategic maneuver is part of Torrent’s broader initiative to strengthen its domestic business, having previously acquired several Indian firms, including Elder Pharma, Unichem Labs, and Curatio. The latest acquisition is poised to elevate Torrent to the position of the fifth-largest pharmaceutical company in India.
Moreover, this deal will enhance Torrent’s presence in new therapeutic areas, particularly ophthalmology. In 2023, JB Chemicals and Pharmaceuticals secured a portfolio of ophthalmic products from Swiss pharmaceutical giant Novartis for 6 million, accompanied by a three-year promotion agreement.
KKR initially invested in JB Pharma in 2020. Gaurav Trehan, CEO of KKR India, expressed pride in the transformation of the company under their management, stating, “We are confident that the merger with Torrent Pharmaceuticals will create new opportunities in the pharmaceutical market.”
Market Position and Capabilities
JB Chemicals and Pharmaceuticals holds a strong position in the treatment of hypertension, generating significant revenue from the Indian market. The company also operates in Russia and South Africa, where it leads in the production of medicinal lozenges.
On the other hand, Torrent Pharmaceuticals boasts eight manufacturing facilities, five of which are FDA-approved, and maintains a dominant presence in cardiology, gastroenterology, and neurology within the Indian market. Additionally, it has a notable footprint in Brazil and Germany. The company’s research and development center, staffed by over 750 scientists, plays a crucial role in its growth strategy.
